Skip to Content

Fluorouracil Dosage

Medically reviewed by Drugs.com. Last updated on Dec 15, 2020.

Applies to the following strengths: 50 mg/mL

Usual Adult Dose for Colorectal Cancer

IN COMBINATION WITH LEUCOVORIN, OR IN COMBINATION WITH LEUCOVORIN AND OXALIPLATIN OR IRINOTECAN:
400 mg/m2 by IV bolus on Day 1, followed by 2400 to 3000 mg/m2 as a continuous IV infusion over 46 hours every 2 weeks

WHEN ADMINISTERED IN A BOLUS DOSING REGIMEN IN COMBINATION WITH LEUCOVORIN:
500 mg/m2 by IV bolus on Days 1, 8, 15, 22, 29, and 36 in 8-week cycles

Use: Adenocarcinoma of the colon and rectum

Usual Adult Dose for Breast Cancer

ADMINISTERED AS A COMPONENT OF A CYCLOPHOSPHAMIDE-BASED MULTIDRUG REGIMEN:
500 or 600 mg/m2 IV on Days 1 and 8 every 28 days for 6 cycles

Use: Adenocarcinoma of the breast

Usual Adult Dose for Stomach Cancer

ADMINISTERED AS A COMPONENT OF A PLATINUM-CONTAINING MULTIDRUG CHEMOTHERAPY REGIMEN:
200 to 1000 mg/m2 IV as a continuous infusion over 24 hours; the frequency of dosing in each cycle and the length of each cycle will depend on the dose of fluorouracil and the specific regimen administered

Use: Gastric adenocarcinoma

Usual Adult Dose for Pancreatic Cancer

ADMINISTERED IN COMBINATION WITH LEUCOVORIN OR AS A COMPONENT OF A MULTIDRUG CHEMOTHERAPY REGIMEN THAT INCLUDES LEUCOVORIN:
400 mg/m2 by IV bolus on Day 1, followed by 2400 mg/m2 IV as a continuous infusion over 46 hours every 2 weeks

Use: Pancreatic adenocarcinoma

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Dose Adjustments

Withhold therapy for the following:
-Angina, myocardial infarction/ischemia, arrhythmia, or heart failure in patients with no history of coronary artery disease or myocardial dysfunction
-Hyperammonemic encephalopathy
-Acute cerebellar syndrome, confusion, disorientation, ataxia, or visual disturbances
-Grade 3 or 4 diarrhea
-Grade 2 or 3 palmar-plantar erythrodysesthesia (hand-foot syndrome)
-Grade 3 or 4 mucositis
-Grade 4 myelosuppression

Upon resolution or improvement to Grade 1 diarrhea, mucositis, myelosuppression, or palmar-plantar erythrodysesthesia, resume administration at a reduced dose.

There is no recommended dose for resumption of therapy if any of the following adverse reactions occur:
-Cardiac toxicity
-Hyperammonemic encephalopathy
-Acute cerebellar syndrome, confusion, disorientation, ataxia, or visual disturbances

Precautions

CONTRAINDICATIONS:
-None

This drug is not recommended for use in children.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:
-This drug is recommended for administration either as an IV bolus or as an IV infusion.
-Do not inject the entire contents of the vial directly into patients.
-Individualize the dose and dosing schedule based on tumor type, the specific regimen administered, disease state, response to treatment, and patient risk factors.

General:
-All dosages are based on patient's actual body weight; however, the estimated lean body weight is used if the patient is obese or if there has been a spurious weight gain due to ascites or other forms of abnormal fluid retention.
-Use is contraindicated in patients who are in a poor nutritional status, have depressed bone marrow function, and those with potentially serious infections.
-This drug is highly toxic with a narrow margin of safety.
-It is recommended that patients be hospitalized during treatment.
-This drug is irritating to the skin; avoid contact with the skin and mucous membranes.

-It is recommended that patients be hospitalized during treatment.
-This drug is irritating to the skin; avoid contact with the skin and mucous membranes.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.